205067_at//IL1B	216243_s_at//IL1RN	volgnummer	title	geo_accession	status	submission_date	last_update_date	type	channel_count	source_name_ch1	organism_ch1	characteristics_ch1	characteristics_ch1.1	characteristics_ch1.2	characteristics_ch1.3	characteristics_ch1.4	characteristics_ch1.5	characteristics_ch1.6	characteristics_ch1.7	characteristics_ch1.8	characteristics_ch1.9	characteristics_ch1.10	characteristics_ch1.11	characteristics_ch1.12	characteristics_ch1.13	characteristics_ch1.14	characteristics_ch1.15	characteristics_ch1.16	molecule_ch1	extract_protocol_ch1	label_ch1	label_protocol_ch1	taxid_ch1	hyb_protocol	scan_protocol	description	description.1	description.2	data_processing	platform_id	contact_name	contact_email	contact_laboratory	contact_department	contact_institute	contact_address	contact_city	contact_state	contact_zip/postal_code	contact_country	contact_web_link	supplementary_file	data_row_count	relation	relation.1	age	cebpa_mutation	cebpa	cell_type	disease_state	evi1_expression	flt3_itd_mutation	flt3_tkd_mutation	gender	idh1	idh2	k.ras_mutation	karyotype	n.ras_mutation	npm1	risk	score	patient	cohort	osi	os	efsi	efs	FAB	OS_days	OS_bin	Age
7.875288598	6.822730148	1174	AML 1174	GSM158762	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158762/suppl/GSM158762.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158762	1	dead	1.48	D	1.48	M5	44	1	59
8.491051376	4.906890596	1188	AML 1188	GSM158763	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 33 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158763/suppl/GSM158763.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM158763	1	dead	1.77	NR	1.77	M1	53	1	33
10.84971785	7.343407822	1197	AML 1197	GSM158764	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 51 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158764/suppl/GSM158764.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M0	GSM158764	1	alive	118.7	EFS	118.7	M0	3561	0	51
7.905687849	5.462706751	1299	AML 1299	GSM158765	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 32 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158765/suppl/GSM158765.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158765	1	alive	84.44	EFS	84.44	M2	2533	0	32
8.758556362	5.236492618	1316	AML 1316	GSM158766	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 19 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158766/suppl/GSM158766.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	19 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158766	1	alive	108.1	EFS	108.1	M1	3243	0	19
7.422905743	5.545350645	1432	AML 1432	GSM158767	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 53 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158767/suppl/GSM158767.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158767	1	dead	0.59	NR	0.59	M1	18	1	53
8.091699834	4.916476644	1551	AML 1551	GSM158768	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158768/suppl/GSM158768.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158768	1	dead	4.47	NR	1.02	M1	134	1	43
7.936048964	6.829088444	1595	AML 1595	GSM158769	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158769/suppl/GSM158769.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158769	1	dead	7.98	Rel/PD	6.83	M1	239	1	43
8.523561956	5.802193217	1747	AML 1747	GSM158770	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 59 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158770/suppl/GSM158770.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158770	1	dead	8.44	Rel/PD	7.75	M2	253	1	59
7.965207091	7.212374788	1766	AML 1766	GSM158771	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 52 years	score: FAB unknown	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158771/suppl/GSM158771.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	NN	Pos	Pos	cytogenetic intermediate	FAB unknown	GSM158771	1	dead	20.01	Rel/PD	17.81	unknown	600	1	52
7.842350343	5.375039431	2169	AML 2169	GSM158772	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158772/suppl/GSM158772.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M1	GSM158772	1	dead	145.9	D	145.9	M1	4377	1	60
6.102238194	7.348728154	2171	AML 2171	GSM158774	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158774/suppl/GSM158774.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158774	1	dead	1.54	NR	1.38	M4	46	1	40
8.139551352	4.906890596	2173	AML 2173	GSM158776	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158776/suppl/GSM158776.CEL.gz	54675	Reanalyzed by: GSE119087		55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Pos	female	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158776	1	alive	210.9	EFS	210.9	M1	6327	0	55
10.80251637	7.572131751	2174	AML 2174	GSM158777	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 45 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158777/suppl/GSM158777.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Pos	cytogenetic intermediate	FAB M5	GSM158777	1	alive	214.2	NR	1.91	M5	6426	0	45
7.818262608	7.73403214	2175	AML 2175	GSM158778	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 57 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158778/suppl/GSM158778.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158778	1	alive	214.5	EFS	214.5	M5	6435	0	57
8.415741768	6.287250643	2176	AML 2176	GSM158779	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 41 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158779/suppl/GSM158779.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158779	1	dead	1.05	NR	1.05	M4	32	1	41
9.202123824	4.906890596	2178	AML 2178	GSM158781	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 46 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158781/suppl/GSM158781.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158781	1	alive	173.9	EFS	173.9	M2	5217	0	46
6.419538892	6.298291731	2179	AML 2179	GSM158782	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158782/suppl/GSM158782.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic good	FAB M4	GSM158782	1	dead	8.41	NR	2.27	M4	252	1	53
8.918266959	6.64096791	2181	AML 2181	GSM158783	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158783/suppl/GSM158783.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158783	1	dead	5.39	Rel/PD	3.65	M5	162	1	39
7.001126665	4.906890596	2182	AML 2182	GSM158784	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 20 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158784/suppl/GSM158784.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158784	1	dead	4.9	NR	2.66	M5	147	1	20
10.28262513	6.619119511	2183	AML 2183	GSM158785	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 52 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158785/suppl/GSM158785.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158785	1	dead	4.3	D	4.3	M4	129	1	52
5.343407822	7.10433666	2184	AML 2184	GSM158786	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 47 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158786/suppl/GSM158786.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158786	1	dead	9.43	Rel/PD	7.62	M5	283	1	47
10.16490693	8.123086751	2185	AML 2185	GSM158787	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 50 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158787/suppl/GSM158787.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158787	1	dead	16.2	Rel/PD	11.47	M5	486	1	50
8.342074668	5.504620392	2186	AML 2186	GSM158788	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158788/suppl/GSM158788.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM158788	1	dead	16.95	Rel/PD	3.61	M5	508	1	39
8.246027981	4.906890596	2187	AML 2187	GSM158789	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 50 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158789/suppl/GSM158789.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158789	1	dead	6.87	Rel/PD	5.29	M1	206	1	50
8.564530601	5.399171094	2188	AML 2188	GSM158790	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 51 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158790/suppl/GSM158790.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158790	1	dead	10.38	NR	2.3	M2	311	1	51
7.894211462	7.014578465	2189	AML 2189	GSM158791	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: FAB M4E	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158791/suppl/GSM158791.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4E	GSM158791	1	alive	138.1	EFS	138.1	M4E	4143	0	53
7.697662633	4.906890596	2192	AML 2192	GSM158794	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 45 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158794/suppl/GSM158794.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158794	1	alive	190.3	EFS	190.3	M1	5709	0	45
9.134939643	4.906890596	2193	AML 2193	GSM158795	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 50 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158795/suppl/GSM158795.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158795	1	dead	13.01	Rel/PD	6.57	M1	390	1	50
8.23935985	5.510961919	2194	AML 2194	GSM158796	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 20 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158796/suppl/GSM158796.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	Pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158796	1	dead	6.87	NR	2.27	M4	206	1	20
9.826866227	6.04220656	2195	AML 2195	GSM158797	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158797/suppl/GSM158797.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158797	1	dead	6.6	Rel/PD	5.06	M4	198	1	49
11.38321827	7.422905743	2196	AML 2196	GSM158798	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 19 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158798/suppl/GSM158798.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	19 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158798	1	dead	10.58	Rel/PD	6.37	M5	317	1	19
6.917670434	4.906890596	2197	AML 2197	GSM158799	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 24 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158799/suppl/GSM158799.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	24 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158799	1	dead	13.14	NR	2.46	M2	394	1	24
10.90643968	7.491853096	2198	AML 2198	GSM158800	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158800/suppl/GSM158800.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158800	1	alive	169.5	EFS	169.5	M5	5085	0	51
6.470862199	4.906890596	2199	AML 2199	GSM158711	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 54 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158711/suppl/GSM158711.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158711	1	alive	175.7	Rel/PD	5.09	M1	5271	0	54
8.339850003	4.906890596	2200	AML 2200	GSM158712	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158712/suppl/GSM158712.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158712	1	dead	109.1	D	109.1	M2	3273	1	38
8.939579214	6.053111336	2201	AML 2201	GSM158713	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 33 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158713/suppl/GSM158713.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158713	1	dead	7.26	NR	3.12	M5	218	1	33
7.410239331	4.906890596	2203	AML 2203	GSM158715	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 37 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158715/suppl/GSM158715.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158715	1	dead	56.15	Rel/PD	12.16	M1	1684	1	37
8.99095486	4.906890596	2204	AML 2204	GSM158716	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158716/suppl/GSM158716.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Pos	Neg	cytogenetic good	FAB M2	GSM158716	1	dead	5.42	D	5.42	M2	163	1	50
8.128252152	5.539158811	2205	AML 2205	GSM158759	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: t(6;9)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158759/suppl/GSM158759.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(6;9)	Neg	Neg	cytogenetic poor	FAB M2	GSM158759	1	dead	14.49	Rel/PD	10.68	M2	435	1	33
9.328450541	6.826548487	2206	AML 2206	GSM158717	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158717/suppl/GSM158717.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Pos	cytogenetic intermediate	FAB M5	GSM158717	1	alive	145.4	Rel/PD	6.74	M5	4362	0	50
9.495255445	6.189824559	2207	AML 2207	GSM158718	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 30 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158718/suppl/GSM158718.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	30 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M1	GSM158718	1	dead	18	Rel/PD	9.66	M1	540	1	30
8.878050913	4.906890596	2208	AML 2208	GSM158719	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 48 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158719/suppl/GSM158719.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158719	1	dead	14.09	Rel/PD	9.43	M2	423	1	48
9.126704473	6.14974712	2209	AML 2209	GSM158720	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158720/suppl/GSM158720.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158720	1	alive	143.6	EFS	143.6	M4	4308	0	55
12.19994834	8.752882366	2210	AML 2210	GSM158721	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158721/suppl/GSM158721.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Pos	Neg	cytogenetic good	FAB M2	GSM158721	1	alive	144.4	EFS	144.4	M2	4332	0	37
9.615077832	4.906890596	2211	AML 2211	GSM158722	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 28 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158722/suppl/GSM158722.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158722	1	alive	149	EFS	149	M2	4470	0	28
8.354910512	6.427941333	2212	AML 2212	GSM158723	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 60 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158723/suppl/GSM158723.CEL.gz	54675	Reanalyzed by: GSE119087		60 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M2	GSM158723	1	dead	7.29	Rel/PD	6.54	M2	219	1	60
9.473299871	4.906890596	2214	AML 2214	GSM158724	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 25 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158724/suppl/GSM158724.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	25 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158724	1	dead	10.05	Rel/PD	9.03	M5	302	1	25
10.29634268	7.859224162	2215	AML 2215	GSM158725	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158725/suppl/GSM158725.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158725	1	alive	113.7	Rel/PD	12.85	M4	3411	0	31
7.196725061	8.069852511	2217	AML 2217	GSM158760	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158760/suppl/GSM158760.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158760	1	alive	124.4	EFS	124.4	M5	3732	0	53
7.8008999	4.906890596	2218	AML 2218	GSM158727	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 40 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158727/suppl/GSM158727.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158727	1	alive	123.4	EFS	123.4	M1	3702	0	40
5.09592442	4.906890596	2219	AML 2219	GSM158728	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158728/suppl/GSM158728.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158728	1	alive	121.2	EFS	121.2	M3	3636	0	31
8.005624549	7.208478242	2220	AML 2220	GSM158729	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 48 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158729/suppl/GSM158729.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158729	1	dead	10.02	Rel/PD	7.03	M5	301	1	48
7.655351829	4.906890596	2222	AML 2222	GSM158730	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158730/suppl/GSM158730.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158730	1	dead	25.89	Rel/PD	22.8	M1	777	1	53
8.539934245	6.21916852	2223	AML 2223	GSM158731	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158731/suppl/GSM158731.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158731	1	dead	14.88	Rel/PD	9.89	M2	446	1	54
8.060695932	4.906890596	2224	AML 2224	GSM158732	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 45 years	score: FAB M6	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158732/suppl/GSM158732.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M6	GSM158732	1	alive	122.9	EFS	122.9	M6	3687	0	45
8.078417702	5.61176256	2225	AML 2225	GSM158733	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 47 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158733/suppl/GSM158733.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158733	1	alive	121.4	EFS	121.4	M4	3642	0	47
5.930737338	4.906890596	2226	AML 2226	GSM158734	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 33 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158734/suppl/GSM158734.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	Other	Pos	Neg	cytogenetic intermediate	FAB M1	GSM158734	1	dead	64.72	Rel/PD	27.53	M1	1942	1	33
11.62908336	7.71630504	2227	AML 2227	GSM158735	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 34 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158735/suppl/GSM158735.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158735	1	dead	17.22	Rel/PD	10.84	M5	517	1	34
7.908092341	7.977852308	2228	AML 2228	GSM158736	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158736/suppl/GSM158736.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	NN	Pos	Neg	cytogenetic poor	FAB M4	GSM158736	1	dead	9.79	D	9.79	M4	294	1	41
8.548821908	7.200653436	2229	AML 2229	GSM158737	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 43 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158737/suppl/GSM158737.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	Other	Neg	Neg	cytogenetic poor	FAB M4	GSM158737	1	dead	15.7	Rel/PD	10.91	M4	471	1	43
9.283551423	6.30560579	2230	AML 2230	GSM158738	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158738/suppl/GSM158738.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158738	1	dead	14.23	D	14.23	M2	427	1	37
9.366103608	7.22881869	2231	AML 2231	GSM158739	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158739/suppl/GSM158739.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158739	1	dead	8.25	Rel/PD	2.66	M4	248	1	43
8.673839056	6.203592714	2233	AML 2233	GSM158740	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 59 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158740/suppl/GSM158740.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM158740	1	dead	1.51	NR	1.51	M1	45	1	59
8.169423979	5.061776198	2234	AML 2234	GSM158741	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158741/suppl/GSM158741.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158741	1	alive	125	Rel/PD	13.54	M2	3750	0	37
10.24638433	6.163901214	2235	AML 2235	GSM158742	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158742/suppl/GSM158742.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM158742	1	alive	120.8	EFS	120.8	M4	3624	0	59
8.476948673	5.708739041	2236	AML 2236	GSM158743	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 36 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158743/suppl/GSM158743.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158743	1	alive	122.8	EFS	122.8	M1	3684	0	36
8.414896604	4.906890596	2237	AML 2237	GSM158744	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 57 years	score: FAB M1	risk: cytogenetic poor	cebpa: single mutant	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158744/suppl/GSM158744.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	Pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM158744	1	dead	5.95	D	5.95	M1	178	1	57
4.906890596	4.906890596	2238	AML 2238	GSM158745	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 21 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158745/suppl/GSM158745.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	21 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158745	1	dead	24.74	D	24.74	M1	742	1	21
8.228337712	6.521992956	2239	AML 2239	GSM158746	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 48 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158746/suppl/GSM158746.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158746	1	alive	114.1	EFS	114.1	M5	3423	0	48
7.888743249	5.727920455	2240	AML 2240	GSM158747	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 48 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158747/suppl/GSM158747.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158747	1	alive	107.8	EFS	107.8	M1	3234	0	48
9.990103964	4.906890596	2241	AML 2241	GSM158748	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158748/suppl/GSM158748.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158748	1	alive	111.5	EFS	111.5	M4	3345	0	53
7.66035251	4.906890596	2242	AML 2242	GSM158749	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: -9q	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158749/suppl/GSM158749.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-9q	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158749	1	alive	123.4	EFS	123.4	M1	3702	0	54
7.970968661	4.906890596	2243	AML 2243	GSM158750	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158750/suppl/GSM158750.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158750	1	alive	35.55	EFS	35.55	M2	1066	0	26
12.36317655	9.016529748	2244	AML 2244	GSM158751	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: +8	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Pos	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158751/suppl/GSM158751.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Pos	+8	Neg	Pos	cytogenetic poor	FAB M5	GSM158751	1	dead	62.13	Rel/PD	50.79	M5	1864	1	51
8.923030298	4.906890596	2245	AML 2245	GSM158752	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158752/suppl/GSM158752.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158752	1	dead	20.47	Rel/PD	16.46	M2	614	1	47
8.38024459	5.426264755	2246	AML 2246	GSM158753	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158753/suppl/GSM158753.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158753	1	alive	100.1	EFS	100.1	M1	3003	0	33
7.364572432	4.906890596	2247	AML 2247	GSM158754	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158754/suppl/GSM158754.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158754	1	dead	8.77	D	8.77	M1	263	1	47
7.949534933	4.906890596	2248	AML 2248	GSM158755	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158755/suppl/GSM158755.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158755	1	dead	21.06	D	21.06	M1	632	1	54
8.739443098	7.807998839	2249	AML 2249	GSM158756	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 29 years	score: FAB M5	risk: cytogenetic good	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158756/suppl/GSM158756.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic good	FAB M5	GSM158756	1	alive	132.6	EFS	132.6	M5	3978	0	29
6.589463893	4.906890596	2251	AML 2251	GSM158758	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158758/suppl/GSM158758.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M2	GSM158758	1	dead	85.82	Rel/PD	2.73	M2	2575	1	55
8.575539247	4.906890596	2252	AML 2252	GSM158801	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 27 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158801/suppl/GSM158801.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	27 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158801	1	dead	23.26	Rel/PD	14.06	M2	698	1	27
8.297833368	8.034523875	2253	AML 2253	GSM158802	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 43 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158802/suppl/GSM158802.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158802	1	dead	17.05	Rel/PD	7.72	M2	512	1	43
8.792139552	6.247927513	2254	AML 2254	GSM158803	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 23 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158803/suppl/GSM158803.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	23 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM158803	1	dead	1.94	D	1.94	M4	58	1	23
7.87036472	4.906890596	2256	AML 2256	GSM158805	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158805/suppl/GSM158805.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158805	1	dead	7.36	D	7.36	M2	221	1	51
9.446669787	4.906890596	2257	AML 2257	GSM158806	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 40 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158806/suppl/GSM158806.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158806	1	dead	9.33	D	9.33	M1	280	1	40
10.54920709	6.772149591	2261	AML 2261	GSM158809	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158809/suppl/GSM158809.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158809	1	dead	3.06	D	3.06	M5	92	1	37
7.938991439	4.906890596	2262	AML 2262	GSM158810	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158810/suppl/GSM158810.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158810	1	dead	13.96	D	13.96	M2	419	1	39
8.077883864	5.51412226	2263	AML 2263	GSM158811	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158811/suppl/GSM158811.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158811	1	alive	150.9	EFS	150.9	M3	4527	0	31
6.864186145	4.906890596	2265	AML 2265	GSM158812	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 21 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158812/suppl/GSM158812.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	21 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158812	1	alive	140.5	EFS	140.5	M3	4215	0	21
10.9586977	4.906890596	2267	AML 2267	GSM158814	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 29 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158814/suppl/GSM158814.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158814	1	alive	143.9	EFS	143.9	M2	4317	0	29
7.687900522	4.906890596	2268	AML 2268	GSM158815	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 56 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158815/suppl/GSM158815.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158815	1	dead	12.88	Rel/PD	11.73	M1	386	1	56
8.539934245	5.475733431	2270	AML 2270	GSM158816	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 41 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158816/suppl/GSM158816.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	+8	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158816	1	dead	6.01	Rel/PD	5.45	M1	180	1	41
8.121015401	4.906890596	2271	AML 2271	GSM158817	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158817/suppl/GSM158817.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158817	1	alive	86.28	EFS	86.28	M2	2588	0	43
9.800738154	7.703211467	2272	AML 2272	GSM158818	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 35 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: +8	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158818/suppl/GSM158818.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	+8	Neg	Pos	cytogenetic poor	FAB M5	GSM158818	1	dead	13.86	Rel/PD	12.58	M5	416	1	35
9.478769619	6.287250643	2274	AML 2274	GSM158820	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 46 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158820/suppl/GSM158820.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic good	FAB M4	GSM158820	1	alive	142	EFS	142	M4	4260	0	46
8.723490302	6.421223299	2275	AML 2275	GSM158821	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 46 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158821/suppl/GSM158821.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158821	1	dead	7.82	Rel/PD	5.98	M5	235	1	46
8.327777171	4.906890596	2276	AML 2276	GSM158822	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158822/suppl/GSM158822.CEL.gz	54675	Reanalyzed by: GSE119087		56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M0	GSM158822	1	dead	1.97	NR	1.71	M0	59	1	56
9.024031502	6.766860144	2278	AML 2278	GSM158823	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 45 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158823/suppl/GSM158823.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158823	1	alive	121.8	EFS	121.8	M5	3654	0	45
10.97656412	8.807998839	2279	AML 2279	GSM158834	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158834/suppl/GSM158834.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158834	1	dead	18.99	Rel/PD	15.57	M4	570	1	54
8.188341576	5.566815154	2280	AML 2280	GSM158835	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 49 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158835/suppl/GSM158835.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158835	1	dead	2.04	NR	2.04	M2	61	1	49
7.765534746	6.506208389	2281	AML 2281	GSM158824	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 20 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158824/suppl/GSM158824.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158824	1	dead	9.82	Rel/PD	8.41	M1	295	1	20
11.82686623	7.984703267	2282	AML 2282	GSM158825	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 44 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158825/suppl/GSM158825.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158825	1	alive	127.3	EFS	127.3	M4	3819	0	44
8.830673649	7.148730779	2283	AML 2283	GSM158826	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 57 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158826/suppl/GSM158826.CEL.gz	54675	Reanalyzed by: GSE119087		57 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic poor	FAB M4	GSM158826	1	dead	4.47	Rel/PD	3.48	M4	134	1	57
8.927777962	4.906890596	2284	AML 2284	GSM158827	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 32 years	score: FAB M6	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158827/suppl/GSM158827.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M6	GSM158827	1	alive	125.2	EFS	125.2	M6	3756	0	32
6.897240426	4.906890596	2286	AML 2286	GSM158829	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158829/suppl/GSM158829.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158829	1	alive	124	Rel/PD	14.92	M1	3720	0	35
8.972118218	6.482202926	2288	AML 2288	GSM158831	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 31 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158831/suppl/GSM158831.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M4	GSM158831	1	dead	16.59	D	16.59	M4	498	1	31
9.06501215	6.840463234	2289	AML 2289	GSM158832	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158832/suppl/GSM158832.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Pos	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158832	1	dead	16.85	D	16.85	M5	506	1	50
7.48703608	5.070389328	2290	AML 2290	GSM158836	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158836/suppl/GSM158836.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158836	1	dead	21.91	Rel/PD	10.71	M2	657	1	41
6.653919873	7.055282436	2291	AML 2291	GSM158837	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158837/suppl/GSM158837.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	+8	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158837	1	dead	27.5	D	27.5	M5	825	1	49
8.488241843	4.972692654	2292	AML 2292	GSM158838	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158838/suppl/GSM158838.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158838	1	dead	24.08	Rel/PD	16.66	M5	722	1	56
10.63263175	6.43629512	2293	AML 2293	GSM158839	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 57 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158839/suppl/GSM158839.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM158839	1	alive	133.1	Rel/PD	10.51	M4	3993	0	57
13.31211717	9.623332832	2296	AML 2296	GSM158840	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158840/suppl/GSM158840.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158840	1	alive	122.6	EFS	122.6	M5	3678	0	38
6.247927513	4.906890596	2297	AML 2297	GSM158841	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158841/suppl/GSM158841.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158841	1	alive	7.69	EFS	7.69	M3	231	0	37
10.28528661	6.464341533	2299	AML 2299	GSM158842	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158842/suppl/GSM158842.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158842	1	dead	10.25	Rel/PD	7.85	M2	308	1	39
7.591709333	5.605849867	2300	AML 2300	GSM158843	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 56 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158843/suppl/GSM158843.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158843	1	dead	3.52	D	3.52	M5	106	1	56
4.906890596	4.906890596	2301	AML 2301	GSM158844	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 24 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: failure	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158844/suppl/GSM158844.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	24 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	failure	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158844	1	dead	2.76	D	2.76	M1	83	1	24
6.116863758	4.906890596	2304	AML 2304	GSM158846	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158846/suppl/GSM158846.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M0	GSM158846	1	dead	13.37	Rel/PD	7.03	M0	401	1	56
7.434628228	6.151777655	2305	AML 2305	GSM158847	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 27 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158847/suppl/GSM158847.CEL.gz	54675	Reanalyzed by: GSE119087		27 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158847	1	alive	92.32	Rel/PD	11.53	M5	2770	0	27
8.657854336	4.906890596	2306	AML 2306	GSM158848	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158848/suppl/GSM158848.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158848	1	dead	12.29	Rel/PD	8.41	M1	369	1	35
8.688250309	5.354028938	2307	AML 2307	GSM158849	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 48 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158849/suppl/GSM158849.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158849	1	dead	1.91	NR	1.91	M3	57	1	48
9.30833903	4.906890596	2326	AML 2326	GSM158850	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 30 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: t(9;22)	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158850/suppl/GSM158850.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	30 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	t(9;22)	Neg	Pos	cytogenetic poor	FAB M2	GSM158850	1	alive	115.7	NR	1.87	M2	3471	0	30
10.84501953	7.546122759	2327	AML 2327	GSM158761	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158761/suppl/GSM158761.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Pos	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M2	GSM158761	1	dead	15.77	NR	2.04	M2	473	1	54
7.338067798	5.197708158	2466	AML 2466	GSM158851	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158851/suppl/GSM158851.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158851	1	alive	86.47	EFS	86.47	M3	2594	0	39
12.36910655	9.822889447	2467	AML 2467	GSM158852	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 44 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158852/suppl/GSM158852.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158852	1	dead	43.6	Rel/PD	13.77	M5	1308	1	44
7.478162893	5.64096791	2468	AML 2468	GSM158853	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 34 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158853/suppl/GSM158853.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158853	1	dead	0.59	NR	0.59	M3	18	1	34
8.668884984	4.906890596	2480	AML 2480	GSM158854	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 34 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158854/suppl/GSM158854.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158854	1	dead	11.86	Rel/PD	3.88	M1	356	1	34
9.157346935	4.906890596	2490	AML 2490	GSM158855	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M6	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158855/suppl/GSM158855.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M6	GSM158855	1	dead	31.28	Rel/PD	13.01	M6	938	1	56
9.949389022	6.017921908	2497	AML 2497	GSM158856	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 20 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158856/suppl/GSM158856.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158856	1	dead	11.04	NR	1.81	M1	331	1	20
7.828453874	5.847996907	2507	AML 2507	GSM158858	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 48 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158858/suppl/GSM158858.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158858	1	alive	126	EFS	126	M2	3780	0	48
5.87036472	5.593951284	2509	AML 2509	GSM158859	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158859/suppl/GSM158859.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158859	1	alive	138.3	EFS	138.3	M3	4149	0	35
5.997744026	4.906890596	2510	AML 2510	GSM158860	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158860/suppl/GSM158860.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158860	1	alive	122.8	EFS	122.8	M3	3684	0	26
8.76884596	4.906890596	2511	AML 2511	GSM158861	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158861/suppl/GSM158861.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158861	1	dead	25.3	Rel/PD	7.98	M2	759	1	35
7.893604905	6.454504938	2514	AML 2514	GSM158862	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 34 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158862/suppl/GSM158862.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM158862	1	dead	4.21	NR	2.43	M5	126	1	34
7.348728154	4.906890596	2516	AML 2516	GSM158863	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 51 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158863/suppl/GSM158863.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158863	1	alive	131.9	EFS	131.9	M3	3957	0	51
8.236014192	4.906890596	2524	AML 2524	GSM158864	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158864/suppl/GSM158864.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158864	1	dead	39.36	Rel/PD	36.6	M1	1181	1	51
8.500642736	8.214319121	2525	AML 2525	GSM158865	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 53 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: NULL	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158865/suppl/GSM158865.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	NULL	Pos	cytogenetic intermediate	FAB M5	GSM158865	1	alive	129.5	EFS	129.5	M5	3885	0	53
7.752882366	7.650333754	2534	AML 2534	GSM158866	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 58 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158866/suppl/GSM158866.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M2	GSM158866	1	dead	4.14	Rel/PD	3.35	M2	124	1	58
6.336283388	6.412781525	2535	AML 2535	GSM158867	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 38 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158867/suppl/GSM158867.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M5	GSM158867	1	dead	7.98	Rel/PD	5.55	M5	239	1	38
8.537994878	7.116863758	2541	AML 2541	GSM158868	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158868/suppl/GSM158868.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM158868	1	dead	1.18	NR	0.62	M5	35	1	56
10.00407998	7.476543706	2542	AML 2542	GSM158869	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 20 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158869/suppl/GSM158869.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Pos	Neg	cytogenetic poor	FAB M4	GSM158869	1	dead	6.14	NR	2.04	M4	184	1	20
7.862947248	4.906890596	2543	AML 2543	GSM158870	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 52 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158870/suppl/GSM158870.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158870	1	dead	7.2	D	7.2	M2	216	1	52
9.234817431	4.906890596	2544	AML 2544	GSM158871	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 37 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158871/suppl/GSM158871.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158871	1	dead	12.16	NR	1.68	M2	365	1	37
8.020702204	4.906890596	2545	AML 2545	GSM158872	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 24 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158872/suppl/GSM158872.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	24 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158872	1	dead	13.01	Rel/PD	8.67	M1	390	1	24
8.833838844	4.906890596	2549	AML 2549	GSM158873	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158873/suppl/GSM158873.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158873	1	alive	162.6	EFS	162.6	M2	4878	0	26
7.546122759	5.008988783	2550	AML 2550	GSM158874	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 55 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158874/suppl/GSM158874.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158874	1	dead	19.55	Rel/PD	12.91	M1	586	1	55
8.089053172	5.578938713	2551	AML 2551	GSM158875	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 23 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158875/suppl/GSM158875.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	23 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158875	1	dead	6.18	D	6.18	M5	185	1	23
8.246027981	4.906890596	2644	AML 2644	GSM158876	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 59 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158876/suppl/GSM158876.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158876	1	dead	0.99	NR	0.99	M1	30	1	59
10.62086129	6.697662633	2647	AML 2647	GSM158877	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 22 years	score: FAB M4E	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158877/suppl/GSM158877.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4E	GSM158877	1	alive	157.7	EFS	157.7	M4E	4731	0	22
6.330916878	5.165911939	2658	AML 2658	GSM158878	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 33 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158878/suppl/GSM158878.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M4	GSM158878	1	alive	134.5	EFS	134.5	M4	4035	0	33
9.703557562	5.339850003	2664	AML 2664	GSM158879	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158879/suppl/GSM158879.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Pos	Neg	cytogenetic poor	FAB M0	GSM158879	1	dead	4.93	NR	1.61	M0	148	1	33
7.953614461	4.906890596	2665	AML 2665	GSM158880	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 45 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: t(6;9)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158880/suppl/GSM158880.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	t(6;9)	Neg	Neg	cytogenetic poor	FAB M5	GSM158880	1	dead	1.84	D	1.84	M5	55	1	45
8.889047583	5.350497247	2666	AML 2666	GSM158881	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M5	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158881/suppl/GSM158881.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	failure	Neg	Neg	unknown	FAB M5	GSM158881	1	dead	13.5	NR	2.33	M5	405	1	35
9.373082645	4.906890596	2668	AML 2668	GSM158882	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158882/suppl/GSM158882.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M0	GSM158882	1	dead	8.77	Rel/PD	7.52	M0	263	1	41
10.58251837	7.339850003	2669	AML 2669	GSM158883	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 45 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158883/suppl/GSM158883.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158883	1	dead	5.75	Rel/PD	5.68	M5	172	1	45
8.821455119	7.329123596	2670	AML 2670	GSM158884	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 47 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: t(6;9)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158884/suppl/GSM158884.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(6;9)	Neg	Neg	cytogenetic poor	FAB M5	GSM158884	1	dead	1.48	NR	1.08	M5	44	1	47
6.346956889	4.906890596	2671	AML 2671	GSM158885	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158885/suppl/GSM158885.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158885	1	alive	127	EFS	127	M3	3810	0	38
11.87916202	5.485426827	2676	AML 2676	GSM158887	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M2	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158887/suppl/GSM158887.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	failure	Neg	Pos	unknown	FAB M2	GSM158887	1	dead	6.51	Rel/PD	5.59	M2	195	1	47
7.910492832	4.99095486	2679	AML 2679	GSM158889	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 39 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158889/suppl/GSM158889.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158889	1	alive	129.3	EFS	129.3	M2	3879	0	39
6.912889336	4.906890596	2680	AML 2680	GSM158890	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 32 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158890/suppl/GSM158890.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M2	GSM158890	1	alive	126.9	EFS	126.9	M2	3807	0	32
8.019590728	6.617651119	2682	AML 2682	GSM158891	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158891/suppl/GSM158891.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M4	GSM158891	1	dead	11.93	Rel/PD	7.1	M4	358	1	56
8.968090752	4.906890596	2683	AML 2683	GSM158892	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158892/suppl/GSM158892.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158892	1	dead	7.1	Rel/PD	7.1	M2	213	1	59
13.29410377	9.466790238	2685	AML 2685	GSM158893	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 42 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: -9q	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158893/suppl/GSM158893.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	pos	neg	Neg	-9q	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158893	1	dead	6.31	Rel/PD	4.17	M4	189	1	42
8.949243096	4.906890596	2686	AML 2686	GSM158894	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 31 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158894/suppl/GSM158894.CEL.gz	54675	Reanalyzed by: GSE119087		31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158894	1	dead	10.87	Rel/PD	9	M1	326	1	31
8.437960088	6.722466024	2687	AML 2687	GSM158895	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158895/suppl/GSM158895.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158895	1	dead	12.12	Rel/PD	7.89	M5	364	1	53
8.681132973	6.229011037	2688	AML 2688	GSM158955	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 40 years	score: FAB unknown	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158955/suppl/GSM158955.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB unknown	GSM158955	1	alive	127.5	Rel/PD	14.42	unknown	3825	0	40
10.18710459	6.622051819	2689	AML 2689	GSM158896	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 53 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158896/suppl/GSM158896.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158896	1	dead	33.38	Rel/PD	12.65	M4	1001	1	53
11.47806175	6.995484519	2692	AML 2692	GSM158898	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 42 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158898/suppl/GSM158898.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158898	1	dead	7.1	Rel/PD	6.8	M5	213	1	42
7.173027465	6.449891473	2694	AML 2694	GSM158956	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 45 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158956/suppl/GSM158956.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M5	GSM158956	1	dead	8.94	Rel/PD	6.57	M5	268	1	45
10.55016959	4.906890596	2695	AML 2695	GSM158899	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 37 years	score: FAB M1	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158899/suppl/GSM158899.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M1	GSM158899	1	alive	122.1	Rel/PD	30.49	M1	3663	0	37
8.268191079	6.598424761	2696	AML 2696	GSM158900	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 46 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158900/suppl/GSM158900.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158900	1	dead	100.2	D	100.2	M4	3006	1	46
8.103287808	6.496654083	2747	AML 2747	GSM158901	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 22 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158901/suppl/GSM158901.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM158901	1	dead	4.21	NR	2.27	M5	126	1	22
8.531771325	5.87036472	2748	AML 2748	GSM158902	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158902/suppl/GSM158902.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158902	1	dead	27.07	Rel/PD	21.85	M4	812	1	47
7.032321287	6.314696526	2749	AML 2749	GSM158903	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158903/suppl/GSM158903.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158903	1	alive	137.7	EFS	137.7	M5	4131	0	38
10.39499851	6.6794801	2750	AML 2750	GSM158904	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158904/suppl/GSM158904.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M2	GSM158904	1	dead	30.32	Rel/PD	11.01	M2	910	1	40
10.22303634	5.022367813	2751	AML 2751	GSM158905	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Pos	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158905/suppl/GSM158905.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Pos	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158905	1	alive	130.4	EFS	130.4	M2	3912	0	31
8.240314329	4.906890596	2753	AML 2753	GSM158907	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 34 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: -9q	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158907/suppl/GSM158907.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-9q	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158907	1	alive	145.1	EFS	145.1	M1	4353	0	34
6.777419716	4.906890596	2754	AML 2754	GSM158908	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 28 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158908/suppl/GSM158908.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158908	1	dead	14.42	Rel/PD	10.45	M1	433	1	28
6.693486957	5.022367813	2756	AML 2756	GSM158909	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 37 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158909/suppl/GSM158909.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158909	1	alive	131.9	EFS	131.9	M2	3957	0	37
7.193771743	4.906890596	2757	AML 2757	GSM158910	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 52 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158910/suppl/GSM158910.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM158910	1	dead	12.98	Rel/PD	11.53	M5	389	1	52
12.57130232	9.262094845	2762	AML 2762	GSM158911	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 23 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158911/suppl/GSM158911.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	23 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Pos	Neg	cytogenetic good	FAB M2	GSM158911	1	alive	147.2	EFS	147.2	M2	4416	0	23
8.667466405	5.153805336	2764	AML 2764	GSM158912	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 21 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158912/suppl/GSM158912.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	21 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158912	1	alive	145.6	EFS	145.6	M2	4368	0	21
8.093813673	4.906890596	2765	AML 2765	GSM158913	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 33 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158913/suppl/GSM158913.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158913	1	dead	17.45	Rel/PD	14.49	M1	524	1	33
8.392746732	7.566054038	2766	AML 2766	GSM158914	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 42 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158914/suppl/GSM158914.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM158914	1	alive	150.4	EFS	150.4	M4	4512	0	42
8.027905997	5.842978832	2767	AML 2767	GSM158915	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 36 years	score: FAB M1	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158915/suppl/GSM158915.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	failure	Neg	Neg	unknown	FAB M1	GSM158915	1	dead	17.45	NR	1.41	M1	524	1	36
7.267723052	4.906890596	2769	AML 2769	GSM158916	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 55 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158916/suppl/GSM158916.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158916	1	alive	132.9	EFS	132.9	M1	3987	0	55
11.33890348	8.218684313	2771	AML 2771	GSM158917	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 52 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158917/suppl/GSM158917.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158917	1	dead	11.93	D	11.93	M5	358	1	52
7.892998093	6.714245518	3115	AML 3115	GSM158918	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 57 years	score: FAB M5	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158918/suppl/GSM158918.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M5	GSM158918	1	alive	135.7	EFS	135.7	M5	4071	0	57
8.500642736	6.469234794	3277	AML 3277	GSM158919	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 28 years	score: FAB M1	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158919/suppl/GSM158919.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M1	GSM158919	1	alive	103.1	NR	2.83	M1	3093	0	28
7.23457796	6.897240426	3278	AML 3278	GSM158920	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 52 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158920/suppl/GSM158920.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158920	1	dead	26.81	Rel/PD	16.56	M3	804	1	52
8.285402219	5.044394119	3279	AML 3279	GSM158921	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 22 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158921/suppl/GSM158921.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM158921	1	alive	141	EFS	141	M3	4230	0	22
8.693835392	5.675251386	3285	AML 3285	GSM158922	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 26 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158922/suppl/GSM158922.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158922	1	alive	112.2	EFS	112.2	M4	3366	0	26
8.201633861	7.123086751	3286	AML 3286	GSM158923	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 55 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158923/suppl/GSM158923.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158923	1	dead	99.06	Rel/PD	81.38	M4	2972	1	55
7.007868243	6.61176256	3289	AML 3289	GSM158924	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 46 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158924/suppl/GSM158924.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M2	GSM158924	1	dead	7.23	D	7.23	M2	217	1	46
8.376776572	5.031218731	3292	AML 3292	GSM158925	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158925/suppl/GSM158925.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158925	1	alive	149	EFS	149	M2	4470	0	41
8.282161767	4.906890596	3293	AML 3293	GSM158926	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 36 years	score: FAB M3	risk: cytogenetic intermediate	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158926/suppl/GSM158926.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic intermediate	FAB M3	GSM158926	1	alive	153.8	Rel/PD	29.34	M3	4614	0	36
7.732676223	4.906890596	3295	AML 3295	GSM158927	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 42 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158927/suppl/GSM158927.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158927	1	dead	22.31	Rel/PD	18.96	M2	669	1	42
7.323730338	6.897240426	3301	AML 3301	GSM158928	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158928/suppl/GSM158928.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Pos	male	neg	neg	Neg	-5/7(q)	Pos	Neg	cytogenetic poor	FAB M5	GSM158928	1	dead	6.44	Rel/PD	5.72	M5	193	1	56
8.365447589	4.906890596	3304	AML 3304	GSM158929	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 58 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158929/suppl/GSM158929.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158929	1	dead	1.35	NR	1.22	M5	40	1	58
8.278914019	5.091699834	3308	AML 3308	GSM158930	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 32 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: t(9;22)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158930/suppl/GSM158930.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	pos	Neg	t(9;22)	Neg	Neg	cytogenetic poor	FAB M1	GSM158930	1	alive	108.1	Rel/PD	31.28	M1	3243	0	32
9.740624044	6.556122818	3309	AML 3309	GSM158931	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 32 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158931/suppl/GSM158931.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158931	1	alive	106.9	EFS	106.9	M4	3207	0	32
7.451952879	4.906890596	3310	AML 3310	GSM158957	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 55 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158957/suppl/GSM158957.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158957	1	dead	45.11	Rel/PD	41.59	M2	1353	1	55
8.297833368	7.068240861	3311	AML 3311	GSM158932	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158932/suppl/GSM158932.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158932	1	dead	5.62	D	5.62	M5	169	1	59
8.873136469	5.61176256	3312	AML 3312	GSM158933	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 19 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158933/suppl/GSM158933.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	19 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158933	1	dead	2.43	D	2.43	M2	73	1	19
7.921840937	5.087462841	3313	AML 3313	GSM158934	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158934/suppl/GSM158934.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M0	GSM158934	1	dead	8.21	D	8.21	M0	246	1	49
7.534497434	5.06608919	3314	AML 3314	GSM158935	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 31 years	score: FAB unknown	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158935/suppl/GSM158935.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB unknown	GSM158935	1	dead	10.74	D	10.74	unknown	322	1	31
8.310158318	6.175923742	3315	AML 3315	GSM158936	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: RAEB-t	risk: cytogenetic poor	cebpa: wild type	karyotype: MDS -7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158936/suppl/GSM158936.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	MDS -7(q)	Pos	Neg	cytogenetic poor	RAEB-t	GSM158936	1	dead	30.39	NR	1.77	RAEB-t	912	1	35
7.298291731	6.327328083	3316	AML 3316	GSM158937	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158937/suppl/GSM158937.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M5	GSM158937	1	dead	0.72	NR	0.72	M5	22	1	43
6.135452784	5.970393538	3317	AML 3317	GSM158938	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 25 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158938/suppl/GSM158938.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	25 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158938	1	dead	67.35	Rel/PD	28.45	M5	2020	1	25
8.967514481	7.082149041	3318	AML 3318	GSM158939	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	gender: male	age: 53 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg			total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158939/suppl/GSM158939.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	NA	NA	Neg		Neg	Neg	cytogenetic poor	FAB M2	GSM158939	1	dead	0.69	NR	0.69	M2	21	1	53
8.388878339	4.906890596	3320	AML 3320	GSM158941	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158941/suppl/GSM158941.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158941	1	dead	6.93	Rel/PD	5.75	M1	208	1	51
11.55281317	7.200653436	3321	AML 3321	GSM158942	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 36 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158942/suppl/GSM158942.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	+8	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158942	1	alive	94.92	EFS	94.92	M5	2848	0	36
6.73470962	5.022367813	3322	AML 3322	GSM158943	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 34 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158943/suppl/GSM158943.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M5	GSM158943	1	dead	9.13	Rel/PD	8.61	M5	274	1	34
8.28771238	6.824004051	3323	AML 3323	GSM158944	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158944/suppl/GSM158944.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M4	GSM158944	1	dead	25.07	Rel/PD	11.53	M4	752	1	37
8.896029603	5.897240426	3324	AML 3324	GSM158945	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M5	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158945/suppl/GSM158945.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M5	GSM158945	1	dead	34.92	NR	2.6	M5	1048	1	26
9.262564702	7.514911265	3325	AML 3325	GSM158946	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158946/suppl/GSM158946.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158946	1	dead	19.19	D	19.19	M4	576	1	41
7.89056829	4.906890596	3326	AML 3326	GSM158947	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 60 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158947/suppl/GSM158947.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M2	GSM158947	1	dead	20.11	Rel/PD	13.11	M2	603	1	60
7.673839056	4.906890596	3327	AML 3327	GSM158948	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158948/suppl/GSM158948.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	Pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158948	1	alive	90.32	EFS	90.32	M1	2710	0	59
9.907791998	6.569855608	3328	AML 3328	GSM158949	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158949/suppl/GSM158949.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M5	GSM158949	1	dead	15.7	Rel/PD	13.14	M5	471	1	41
8.797012978	6.400879436	3334	AML 3334	GSM158950	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158950/suppl/GSM158950.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	RAEB-t	GSM158950	1	dead	9.2	D	9.2	RAEB-t	276	1	43
7.416164165	5.070389328	3481	AML 3481	GSM158951	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 46 years	score: RAEB	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158951/suppl/GSM158951.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	RAEB	GSM158951	1	dead	12.06	Rel/PD	5.72	RAEB	362	1	46
6.786596362	7.070389328	3482	AML 3482	GSM158952	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158952/suppl/GSM158952.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M5	GSM158952	1	dead	7.89	Rel/PD	5.59	M5	237	1	43
6.903279342	5.409390936	3483	AML 3483	GSM158953	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 45 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158953/suppl/GSM158953.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158953	1	dead	19.22	Rel/PD	9.03	M1	577	1	45
11.18096585	7.561478892	3484	AML 3484	GSM158954	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 60 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: Neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158954/suppl/GSM158954.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	Neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158954	1	alive	94.88	EFS	94.88	M4	2846	0	60
7.896029603	5.285402219	4333	AML 4333	GSM159041	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 31 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159041/suppl/GSM159041.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM159041	2	dead	1.54	NR	1.54	M5	46	1	31
9.490048599	5.173926932	4334	AML 4334	GSM159042	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159042/suppl/GSM159042.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg		Pos	Pos	cytogenetic intermediate	FAB M4	GSM159042	2	alive	82.76	EFS	82.76	M4	2483	0	54
7.503825738	5.560714954	4335	AML 4335	GSM159043	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 44 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159043/suppl/GSM159043.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159043	2	alive	44.19	EFS	44.19	M1	1326	0	44
8.876209958	4.906890596	4336	AML 4336	GSM159044	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 30 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159044/suppl/GSM159044.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	30 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	RAEB-t	GSM159044	2	alive	82.63	Rel/PD	26.71	RAEB-t	2479	0	30
8.554205105	5.197708158	4337	AML 4337	GSM159045	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159045/suppl/GSM159045.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB M0	GSM159045	2	alive	84.24	Rel/PD	8.54	M0	2527	0	56
6.997744026	5.185866545	4338	AML 4338	GSM159046	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159046/suppl/GSM159046.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M0	GSM159046	2	dead	18.2	Rel/PD	16.76	M0	546	1	50
11.63544606	7.256444596	4339	AML 4339	GSM159047	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 20 years	score: RAEB	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159047/suppl/GSM159047.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	RAEB	GSM159047	2	alive	97.28	Rel/PD	23.16	RAEB	2918	0	20
7.960001932	5.708739041	4340	AML 4340	GSM159048	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159048/suppl/GSM159048.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159048	2	dead	2.43	D	2.43	M2	73	1	39
8.242221395	6.091699834	4341	AML 4341	GSM159049	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159049/suppl/GSM159049.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Pos	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	RAEB-t	GSM159049	2	alive	87.46	EFS	87.46	RAEB-t	2624	0	53
8.354910512	6.157852169	5282	AML 5282	GSM159036	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159036/suppl/GSM159036.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159036	2	dead	7.82	Rel/PD	6.9	M5	235	1	56
8.458611673	4.906890596	5283	AML 5283	GSM159037	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 35 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159037/suppl/GSM159037.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM159037	2	alive	76.58	EFS	76.58	M2	2297	0	35
8.875288598	4.906890596	5284	AML 5284	GSM159038	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 41 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159038/suppl/GSM159038.CEL.gz	54675	Reanalyzed by: GSE119087		41 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159038	2	dead	59.4	Rel/PD	33.51	M2	1782	1	41
9.182394353	5.783980414	5285	AML 5285	GSM159039	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 59 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159039/suppl/GSM159039.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159039	2	alive	62.75	Rel/PD	59.5	M4	1882	0	59
8.28771238	5.232660757	5286	AML 5286	GSM158958	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 57 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158958/suppl/GSM158958.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158958	2	dead	8.31	Rel/PD	8.31	M2	249	1	57
7.885086225	5.981852653	5356	AML 5356	GSM159040	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB unknown	risk: cytogenetic poor	cebpa: wild type	karyotype: t(6;9)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159040/suppl/GSM159040.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(6;9)	Pos	Neg	cytogenetic poor	FAB unknown	GSM159040	2	alive	7.23	EFS	7.23	unknown	217	0	40
8.868205227	5.472487771	5357	AML 5357	GSM159050	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 43 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159050/suppl/GSM159050.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM159050	2	dead	1.28	NR	1.28	M2	38	1	43
7.546122759	7.490249211	5358	AML 5358	GSM159051	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159051/suppl/GSM159051.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M5	GSM159051	2	alive	69.16	EFS	69.16	M5	2075	0	40
8.17990909	5.830356747	5359	AML 5359	GSM159052	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: t(6;9)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159052/suppl/GSM159052.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(6;9)	Pos	Neg	cytogenetic poor	FAB M2	GSM159052	2	alive	73.89	EFS	73.89	M2	2217	0	53
9.081350281	4.906890596	5360	AML 5360	GSM159160	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 29 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159160/suppl/GSM159160.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM159160	2	dead	17.87	Rel/PD	16.26	M1	536	1	29
7.744833837	6.249824549	5361	AML 5361	GSM159161	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 28 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159161/suppl/GSM159161.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic poor	FAB M2	GSM159161	2	alive	76.16	EFS	76.16	M2	2285	0	28
8.304237225	6.345183447	5362	AML 5362	GSM159053	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159053/suppl/GSM159053.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M2	GSM159053	2	dead	11.6	Rel/PD	6.51	M2	348	1	53
8.022367813	7.665335917	5363	AML 5363	GSM159054	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 55 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159054/suppl/GSM159054.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159054	2	alive	75.3	EFS	75.3	M4	2259	0	55
9.316055209	5.773468928	5364	AML 5364	GSM159055	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159055/suppl/GSM159055.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159055	2	dead	1.94	NR	1.94	M2	58	1	60
8.078417702	6.64096791	5365	AML 5365	GSM158959	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 42 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158959/suppl/GSM158959.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158959	2	alive	64.23	EFS	64.23	M4	1927	0	42
9.444600814	5.354028938	6236	AML 6236	GSM159056	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 59 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159056/suppl/GSM159056.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic poor	FAB M2	GSM159056	2	dead	10.97	Rel/PD	8.54	M2	329	1	59
8.288635409	6.061776198	6237	AML 6237	GSM158960	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158960/suppl/GSM158960.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158960	2	alive	95.44	EFS	95.44	M1	2863	0	59
8.621685607	6.213347282	6238	AML 6238	GSM159162	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 30 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159162/suppl/GSM159162.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	30 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M4	GSM159162	2	dead	19.68	Rel/PD	8.71	M4	590	1	30
8.70494111	5.675251386	6239	AML 6239	GSM158961	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 42 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158961/suppl/GSM158961.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM158961	2	dead	2.37	D	2.37	M2	71	1	42
8.600284623	6.031218731	6240	AML 6240	GSM159163	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159163/suppl/GSM159163.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M2	GSM159163	2	dead	2.27	D	2.27	M2	68	1	55
7.694880193	6.671010241	6241	AML 6241	GSM159164	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 48 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159164/suppl/GSM159164.CEL.gz	54675	Reanalyzed by: GSE119087		48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159164	2	alive	81.58	EFS	81.58	M4	2447	0	48
7.701826258	4.906890596	6242	AML 6242	GSM159165	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 52 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159165/suppl/GSM159165.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159165	2	alive	85.29	Rel/PD	21.36	M2	2559	0	52
7.888134388	5.266786541	6244	AML 6244	GSM159167	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 57 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159167/suppl/GSM159167.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159167	2	alive	74.94	EFS	74.94	M2	2248	0	57
7.437127844	5.125155131	6245	AML 6245	GSM159168	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 55 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159168/suppl/GSM159168.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159168	2	alive	75.43	EFS	75.43	M2	2263	0	55
8.268191079	4.906890596	6246	AML 6246	GSM158962	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 25 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158962/suppl/GSM158962.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	25 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158962	2	alive	80.56	Rel/PD	18.3	M1	2417	0	25
8.8008999	6.427941333	6247	AML 6247	GSM158963	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158963/suppl/GSM158963.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M2	GSM158963	2	dead	6.31	NR	4.6	M2	189	1	60
7.386293635	4.906890596	6358	AML 6358	GSM158964	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 45 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158964/suppl/GSM158964.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M2	GSM158964	2	dead	6.87	NR	2.86	M2	206	1	45
8.168922782	4.906890596	6359	AML 6359	GSM159169	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: RAEB-t	risk: cytogenetic poor	cebpa: wild type	karyotype: MDS complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159169/suppl/GSM159169.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	MDS complex	Neg	Neg	cytogenetic poor	RAEB-t	GSM159169	2	dead	10.09	Rel/PD	5.26	RAEB-t	303	1	53
6.173926932	5.439623138	6360	AML 6360	GSM159057	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 30 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159057/suppl/GSM159057.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	30 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159057	2	alive	77.47	EFS	77.47	M2	2324	0	30
8.436711542	7.561478892	6361	AML 6361	GSM159170	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159170/suppl/GSM159170.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	RAEB-t	GSM159170	2	dead	30.39	NR	2.33	RAEB-t	912	1	60
7.764871591	4.906890596	6362	AML 6362	GSM159058	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 29 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: nd	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159058/suppl/GSM159058.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	nd	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159058	2	alive	65.71	EFS	65.71	M1	1971	0	29
8.151270289	7.130313146	6363	AML 6363	GSM159059	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 23 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos?	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159059/suppl/GSM159059.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	23 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos?	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM159059	2	alive	73.46	EFS	73.46	M4	2204	0	23
6.447909749	6.966937979	6364	AML 6364	GSM159060	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159060/suppl/GSM159060.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M5	GSM159060	2	alive	65.05	EFS	65.05	M5	1952	0	49
7.41869595	7.411087227	6365	AML 6365	GSM159061	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159061/suppl/GSM159061.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM159061	2	dead	2.86	NR	2.86	M4	86	1	56
7.292781749	4.906890596	6366	AML 6366	GSM159062	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 57 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159062/suppl/GSM159062.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M2	GSM159062	2	dead	0.89	NR	0.89	M2	27	1	57
6.87036472	5.930737338	6367	AML 6367	GSM159063	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 48 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: abn(3q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159063/suppl/GSM159063.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	abn(3q)	Neg	Neg	cytogenetic poor	FAB M1	GSM159063	2	dead	14.75	Rel/PD	9.82	M1	442	1	48
8.12722055	7.025693274	6368	AML 6368	GSM159064	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 49 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159064/suppl/GSM159064.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M5	GSM159064	2	alive	76.45	EFS	76.45	M5	2294	0	49
6.296457407	4.906890596	6369	AML 6369	GSM159065	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 53 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159065/suppl/GSM159065.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159065	2	alive	74.58	Rel/PD	41.26	M2	2237	0	53
7.962896005	4.906890596	6370	AML 6370	GSM159066	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 57 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: -9q	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159066/suppl/GSM159066.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	-9q	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159066	2	dead	10.64	Rel/PD	7.62	M1	319	1	57
8.828453874	4.906890596	6371	AML 6371	GSM159067	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 43 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159067/suppl/GSM159067.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M2	GSM159067	2	alive	64.3	Rel/PD	61.5	M2	1929	0	43
8.831307244	4.968090752	6372	AML 6372	GSM159068	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 41 years	score: FAB M1	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159068/suppl/GSM159068.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M1	GSM159068	2	alive	64.1	EFS	64.1	M1	1923	0	41
7.929554316	6.232660757	6373	AML 6373	GSM159069	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: RAEB-t	risk: cytogenetic poor	cebpa: wild type	karyotype: MDS complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159069/suppl/GSM159069.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	MDS complex	Neg	Neg	cytogenetic poor	RAEB-t	GSM159069	2	dead	3.09	D	3.09	RAEB-t	93	1	56
8.445428759	5.09592442	6374	AML 6374	GSM159070	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 55 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159070/suppl/GSM159070.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159070	2	alive	64.62	EFS	64.62	M2	1939	0	55
9.294391002	4.906890596	6375	AML 6375	GSM159071	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 58 years	score: FAB unknown	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159071/suppl/GSM159071.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB unknown	GSM159071	2	dead	0.82	NR	0.82	unknown	25	1	58
8.079484784	4.906890596	6376	AML 6376	GSM158965	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 36 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: -9q	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158965/suppl/GSM158965.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-9q	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158965	2	alive	64.66	EFS	64.66	M1	1940	0	36
7.727239777	5.623515741	6378	AML 6378	GSM159072	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159072/suppl/GSM159072.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159072	2	alive	65.25	EFS	65.25	M4	1958	0	47
9.051752739	6.169925001	6379	AML 6379	GSM159073	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159073/suppl/GSM159073.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159073	2	alive	56.21	EFS	56.21	M4	1686	0	50
7.911092332	5.357552005	6448	AML 6448	GSM159074	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159074/suppl/GSM159074.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	RAEB-t	GSM159074	2	alive	62.59	EFS	62.59	RAEB-t	1878	0	50
7.793765857	5.385431037	6464	AML 6464	GSM158966	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 25 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158966/suppl/GSM158966.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	25 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158966	2	alive	123.4	EFS	123.4	M2	3702	0	25
9.732506644	4.906890596	6465	AML 6465	GSM158967	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158967/suppl/GSM158967.CEL.gz	54675	Reanalyzed by: GSE119087		54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158967	2	dead	15.21	Rel/PD	9.59	M1	456	1	54
6.21916852	4.906890596	6714	AML 6714	GSM159075	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159075/suppl/GSM159075.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM159075	2	dead	19.91	NR	2.43	M5	597	1	47
7.720415285	5.697662633	6715	AML 6715	GSM158968	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M4E	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158968/suppl/GSM158968.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M4E	GSM158968	2	dead	47.28	Rel/PD	19.65	M4E	1418	1	39
8.465974465	7.147713722	6717	AML 6717	GSM158969	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 58 years	score: FAB M5	risk: cytogenetic good	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158969/suppl/GSM158969.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic good	FAB M5	GSM158969	2	alive	198.7	EFS	198.7	M5	5961	0	58
9.715447263	4.906890596	6719	AML 6719	GSM158970	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158970/suppl/GSM158970.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158970	2	alive	170	EFS	170	M2	5100	0	33
10.21650337	6.692092375	6720	AML 6720	GSM158971	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 38 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158971/suppl/GSM158971.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM158971	2	dead	11.33	Rel/PD	7.69	M1	340	1	38
6.334496768	4.906890596	6721	AML 6721	GSM158972	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 39 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158972/suppl/GSM158972.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M5	GSM158972	2	dead	36.83	Rel/PD	11.96	M5	1105	1	39
10.59273733	7.586464526	6723	AML 6723	GSM158973	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 32 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158973/suppl/GSM158973.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM158973	2	dead	57.49	Rel/PD	51.52	M5	1725	1	32
10.71390198	7.694183743	6724	AML 6724	GSM158974	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158974/suppl/GSM158974.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158974	2	dead	10.35	D	10.35	M5	310	1	26
8.057991723	4.906890596	6730	AML 6730	GSM158975	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158975/suppl/GSM158975.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic good	FAB M3	GSM158975	2	dead	29.73	Rel/PD	9.23	M3	892	1	49
7.369815424	7.489446599	6732	AML 6732	GSM158976	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158976/suppl/GSM158976.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158976	2	dead	8.38	Rel/PD	7.23	M5	251	1	38
8.318768743	4.906890596	6734	AML 6734	GSM158977	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158977/suppl/GSM158977.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158977	2	dead	9.89	Rel/PD	6.08	M1	297	1	59
8.45779126	4.906890596	6735	AML 6735	GSM158978	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158978/suppl/GSM158978.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158978	2	alive	148	EFS	148	M1	4440	0	55
12.38906663	8.788881432	6880	AML 6880	GSM158979	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 48 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158979/suppl/GSM158979.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M2	GSM158979	2	dead	16.66	Rel/PD	8.71	M2	500	1	48
10.25432003	7.676662335	6881	AML 6881	GSM158980	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: failure	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158980/suppl/GSM158980.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	failure	Pos	Neg	cytogenetic good	FAB M4	GSM158980	2	dead	69.62	Rel/PD	19.78	M4	2089	1	37
7.354910512	6.311067102	6882	AML 6882	GSM158981	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158981/suppl/GSM158981.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M5	GSM158981	2	alive	158.8	EFS	158.8	M5	4764	0	37
12.44491135	9.21916852	6883	AML 6883	GSM159076	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 42 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159076/suppl/GSM159076.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159076	2	dead	16	Rel/PD	8.51	M4	480	1	42
7.752882366	5.270528942	6884	AML 6884	GSM159077	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 19 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159077/suppl/GSM159077.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	19 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159077	2	dead	8.48	Rel/PD	4.6	M4	254	1	19
9.77939106	7.719731057	6885	AML 6885	GSM159078	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 42 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159078/suppl/GSM159078.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Pos	Pos	cytogenetic intermediate	FAB M5	GSM159078	2	alive	171.7	EFS	171.7	M5	5151	0	42
8.449973986	5.108524457	6887	AML 6887	GSM159079	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 41 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159079/suppl/GSM159079.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159079	2	dead	16.99	Rel/PD	14.65	M1	510	1	41
9.40599236	8.573647187	6888	AML 6888	GSM159080	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: abn(3q)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159080/suppl/GSM159080.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	abn(3q)	Neg	Neg	cytogenetic poor	FAB M5	GSM159080	2	dead	70.08	NR	1.71	M5	2102	1	43
8.329572126	4.906890596	6889	AML 6889	GSM159081	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 36 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159081/suppl/GSM159081.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	36 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM159081	2	alive	164.5	EFS	164.5	M2	4935	0	36
8.700092875	5.529820947	6891	AML 6891	GSM159083	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	gender: male	age: 56 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg			total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159083/suppl/GSM159083.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	NA	NA	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM159083	2	dead	11.99	Rel/PD	10.81	M4	360	1	56
9.33516701	5.791814071	6892	AML 6892	GSM159084	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 21 years	score: FAB M1	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159084/suppl/GSM159084.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	21 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M1	GSM159084	2	alive	168.4	Rel/PD	9.99	M1	5052	0	21
9.370469461	4.906890596	6945	AML 6945	GSM159085	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159085/suppl/GSM159085.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159085	2	dead	9	Rel/PD	3.61	M4	270	1	33
9.650692767	4.906890596	6947	AML 6947	GSM159086	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 21 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159086/suppl/GSM159086.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	21 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159086	2	dead	85.78	Rel/PD	75.27	M1	2573	1	21
9.05039286	7.029011087	6948	AML 6948	GSM159087	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 22 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159087/suppl/GSM159087.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Pos	cytogenetic poor	FAB M5	GSM159087	2	dead	11.96	Rel/PD	9.36	M5	359	1	22
7.796364138	6.986410935	6949	AML 6949	GSM159088	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 33 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159088/suppl/GSM159088.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159088	2	dead	15.47	Rel/PD	5.91	M1	464	1	33
8.416164165	6.108524457	6952	AML 6952	GSM159089	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 52 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159089/suppl/GSM159089.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	52 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159089	2	dead	4.93	Rel/PD	2.79	M4	148	1	52
7.358431429	4.906890596	6953	AML 6953	GSM159090	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 55 years	score: FAB M6	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159090/suppl/GSM159090.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M6	GSM159090	2	alive	149.3	EFS	149.3	M6	4479	0	55
5.10433666	6.14974712	6955	AML 6955	GSM159091	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159091/suppl/GSM159091.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	+8	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159091	2	alive	169.4	EFS	169.4	M2	5082	0	31
7.702519029	4.906890596	6974	AML 6974	GSM159092	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 32 years	score: FAB M6	risk: cytogenetic intermediate	cebpa: wild type	karyotype: +8	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: nd	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159092/suppl/GSM159092.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	nd	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	+8	Pos	Neg	cytogenetic intermediate	FAB M6	GSM159092	2	dead	22.34	Rel/PD	13.93	M6	670	1	32
8.395319911	4.906890596	6975	AML 6975	GSM159093	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: -9q	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159093/suppl/GSM159093.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	-9q	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159093	2	alive	128.5	EFS	128.5	M4	3855	0	54
5.03562391	6.195741293	6976	AML 6976	GSM159094	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159094/suppl/GSM159094.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M0	GSM159094	2	alive	129.5	EFS	129.5	M0	3885	0	31
7.233619677	5.62058641	6977	AML 6977	GSM159095	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159095/suppl/GSM159095.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M5	GSM159095	2	dead	33.12	Rel/PD	25.1	M5	994	1	33
9.29553937	7.233619677	6979	AML 6979	GSM159096	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 56 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159096/suppl/GSM159096.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159096	2	dead	10.15	Rel/PD	8.25	M2	304	1	56
9.422485316	4.906890596	6982	AML 6982	GSM159099	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 47 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159099/suppl/GSM159099.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM159099	2	dead	9.13	NR	2.37	M1	274	1	47
9.160627797	4.906890596	7051	AML 7051	GSM159100	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159100/suppl/GSM159100.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159100	2	dead	3.12	NR	1.05	M1	94	1	59
7.553053253	5.581953751	7052	AML 7052	GSM159101	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 34 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159101/suppl/GSM159101.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	Other	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159101	2	alive	170.7	EFS	170.7	M2	5121	0	34
8.556122818	4.906890596	7053	AML 7053	GSM159102	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 29 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159102/suppl/GSM159102.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM159102	2	dead	9.59	Rel/PD	7.46	M1	288	1	29
8.193278936	4.906890596	7054	AML 7054	GSM159103	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 44 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159103/suppl/GSM159103.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M4	GSM159103	2	dead	16.33	D	16.33	M4	490	1	44
7.327328083	8.283551423	7055	AML 7055	GSM159104	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 43 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159104/suppl/GSM159104.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159104	2	dead	13.11	Rel/PD	10.12	M2	393	1	43
9.951576139	4.906890596	7057	AML 7057	GSM159106	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159106/suppl/GSM159106.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159106	2	dead	11.5	Rel/PD	10.51	M1	345	1	56
13.32049032	10.34529435	7058	AML 7058	GSM159107	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 54 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159107/suppl/GSM159107.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159107	2	alive	111.1	EFS	111.1	M1	3333	0	54
10.00183038	4.906890596	7059	AML 7059	GSM159108	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 43 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159108/suppl/GSM159108.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M0	GSM159108	2	dead	32.3	Rel/PD	31.34	M0	969	1	43
7.748863715	4.906890596	7061	AML 7061	GSM159109	Public on Mar 12 2008	Jan 29 2007	Aug 28 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 31 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: nd	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159109/suppl/GSM159109.CEL.gz	54675	Reanalyzed by: GSE119087		31 years	nd	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159109	2	dead	19.35	Rel/PD	9.2	M1	580	1	31
9.564911611	5.339850003	7062	AML 7062	GSM159110	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: nd	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159110/suppl/GSM159110.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	nd	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM159110	2	dead	132	D	132	M2	3960	1	53
8.397888508	4.906890596	7063	AML 7063	GSM159111	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 48 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159111/suppl/GSM159111.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM159111	2	dead	85.49	D	85.49	M3	2565	1	48
8.468827655	4.906890596	7067	AML 7067	GSM159113	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 42 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159113/suppl/GSM159113.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	42 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	pos	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M1	GSM159113	2	dead	6.87	Rel/PD	4.86	M1	206	1	42
9.116863758	7.005624549	7069	AML 7069	GSM159114	Public on Mar 12 2008	Jan 29 2007	Jul 28 2011	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	gender: male	age: 61 years	score: FAB M2	risk: cytogenetic poor	cebpa: wilde type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg			total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.		The CEL file for this Sample is not available.	MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	NONE	54675			61 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	NA	NA	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M2	GSM159114	2	dead	6.67	Rel/PD	4.93	M2	200	1	61
13.30155335	10.91318862	7070	AML 7070	GSM159115	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159115/suppl/GSM159115.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg		Pos	Neg	cytogenetic intermediate	FAB M4	GSM159115	2	dead	10.61	NR	1.28	M4	318	1	39
10.18338726	8.361066489	7071	AML 7071	GSM159116	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 50 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159116/suppl/GSM159116.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159116	2	dead	73.46	D	73.46	M2	2204	1	50
10.31831684	7.231701199	7072	AML 7072	GSM159117	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159117/suppl/GSM159117.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M4	GSM159117	2	dead	0.72	NR	0.72	M4	22	1	60
6.48058827	6.338067798	7073	AML 7073	GSM159118	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159118/suppl/GSM159118.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159118	2	alive	81.71	EFS	81.71	M4	2451	0	37
12.55458885	7.647458426	7074	AML 7074	GSM159119	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 45 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159119/suppl/GSM159119.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159119	2	dead	22.64	Rel/PD	8.84	M4	679	1	45
9.831782257	6.371558863	7075	AML 7075	GSM159120	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 55 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159120/suppl/GSM159120.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159120	2	alive	92.78	EFS	92.78	M4	2783	0	55
10.21928955	5.03562391	7076	AML 7076	GSM159121	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159121/suppl/GSM159121.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB M0	GSM159121	2	dead	51.71	Rel/PD	40.25	M0	1551	1	40
12.52779464	9.734878941	7077	AML 7077	GSM159122	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: RAEB	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159122/suppl/GSM159122.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	RAEB	GSM159122	2	alive	95.38	NR	3.35	RAEB	2861	0	53
10.34151882	7.830356747	7078	AML 7078	GSM159123	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159123/suppl/GSM159123.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159123	2	alive	91.17	EFS	91.17	M5	2735	0	55
8.539158811	6.169925001	7079	AML 7079	GSM159124	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 28 years	score: FAB M5	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159124/suppl/GSM159124.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M5	GSM159124	2	alive	81.61	EFS	81.61	M5	2448	0	28
9.078417702	4.906890596	7081	AML 7081	GSM158982	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 43 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158982/suppl/GSM158982.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158982	2	alive	70.08	EFS	70.08	M2	2102	0	43
6.636624621	5.251719093	7082	AML 7082	GSM158983	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 29 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158983/suppl/GSM158983.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM158983	2	dead	40.02	Rel/PD	16.62	M1	1201	1	29
8.019590728	4.906890596	7114	AML 7114	GSM158984	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 54 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158984/suppl/GSM158984.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM158984	2	dead	0.72	NR	0.72	M2	22	1	54
7.150762744	5.083213368	7115	AML 7115	GSM158985	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158985/suppl/GSM158985.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M4	GSM158985	2	dead	6.01	Rel/PD	6.01	M4	180	1	39
9.134939643	6.842978832	7119	AML 7119	GSM159125	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 57 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159125/suppl/GSM159125.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159125	2	dead	6.9	Rel/PD	4.6	M2	207	1	57
8.991805255	4.906890596	7120	AML 7120	GSM159126	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 51 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159126/suppl/GSM159126.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M1	GSM159126	2	dead	0.62	NR	0.62	M1	19	1	51
9.049031698	5.635173947	7121	AML 7121	GSM159127	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M2	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159127/suppl/GSM159127.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	failure	Neg	Pos	unknown	FAB M2	GSM159127	2	dead	6.21	NR	3.75	M2	186	1	49
12.49637946	8.044940491	7124	AML 7124	GSM158986	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 59 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158986/suppl/GSM158986.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM158986	2	dead	1.12	NR	1.12	M5	34	1	59
12.61157815	8.727920455	7125	AML 7125	GSM158987	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 48 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158987/suppl/GSM158987.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM158987	2	alive	128.7	EFS	128.7	M4	3861	0	48
8.581953751	4.906890596	7127	AML 7127	GSM158988	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 44 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158988/suppl/GSM158988.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM158988	2	dead	19.35	Rel/PD	14.36	M1	580	1	44
8.888438851	4.906890596	7131	AML 7131	GSM158990	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 55 years	score: FAB M1	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158990/suppl/GSM158990.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	failure	Neg	Pos	unknown	FAB M1	GSM158990	2	dead	2.43	NR	2.43	M1	73	1	55
7.783980414	6.862947248	7137	AML 7137	GSM158992	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 58 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158992/suppl/GSM158992.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg		Neg	Neg	cytogenetic intermediate	FAB M5	GSM158992	2	alive	58.15	Rel/PD	9.49	M5	1744	0	58
9.33516701	6.690696444	7139	AML 7139	GSM158993	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 53 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158993/suppl/GSM158993.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM158993	2	dead	3.98	D	3.98	M4	119	1	53
8.795390331	6.078951341	7142	AML 7142	GSM158994	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 49 years	score: FAB M2	risk: cytogenetic poor	cebpa: double mutant	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158994/suppl/GSM158994.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	49 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB M2	GSM158994	2	alive	83.19	EFS	83.19	M2	2496	0	49
7.968090752	5.608809243	7143	AML 7143	GSM158995	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 27 years	score: FAB unknown	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158995/suppl/GSM158995.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	27 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Pos	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB unknown	GSM158995	2	dead	2.76	NR	1.48	unknown	83	1	27
8.284477118	6.528258743	7144	AML 7144	GSM159129	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 51 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159129/suppl/GSM159129.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg		Pos	Pos	cytogenetic intermediate	FAB M5	GSM159129	2	dead	11.3	Rel/PD	5.06	M5	339	1	51
8.563005553	5.409390936	7145	AML 7145	GSM158996	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 50 years	score: FAB M2	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158996/suppl/GSM158996.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	pos	Neg	failure	Neg	Pos	unknown	FAB M2	GSM158996	2	dead	8.51	Rel/PD	8.11	M2	255	1	50
10.28436144	6.089582893	7147	AML 7147	GSM158997	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 59 years	score: FAB M1	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158997/suppl/GSM158997.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	failure	Neg	Neg	unknown	FAB M1	GSM158997	2	dead	0.69	NR	0.69	M1	21	1	59
8.527477006	4.906890596	7149	AML 7149	GSM158998	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 37 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158998/suppl/GSM158998.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M5	GSM158998	2	dead	50.4	D	50.4	M5	1512	1	37
11.06763603	6.665335917	7150	AML 7150	GSM158999	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 20 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM158nnn/GSM158999/suppl/GSM158999.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	20 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4	GSM158999	2	dead	28.12	Rel/PD	7.95	M4	844	1	20
9.512147859	5.343407822	7151	AML 7151	GSM159000	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 32 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159000/suppl/GSM159000.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	32 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159000	2	dead	20.07	Rel/PD	10.68	M1	602	1	32
8.513332824	7.811856314	7153	AML 7153	GSM159001	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 22 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159001/suppl/GSM159001.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159001	2	alive	97.25	EFS	97.25	M5	2918	0	22
9.243412032	4.906890596	7154	AML 7154	GSM159002	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 48 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159002/suppl/GSM159002.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	pos	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159002	2	alive	127.1	EFS	127.1	M1	3813	0	48
9.35380846	6.026800059	7163	AML 7163	GSM159003	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 54 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159003/suppl/GSM159003.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M5	GSM159003	2	dead	15.01	NR	2.76	M5	450	1	54
9.084276911	4.906890596	7164	AML 7164	GSM159130	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 48 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159130/suppl/GSM159130.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159130	2	dead	54.93	Rel/PD	54.28	M1	1648	1	48
6.472487771	6.947198584	7166	AML 7166	GSM159131	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 44 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159131/suppl/GSM159131.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	44 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB M5	GSM159131	2	alive	74.68	EFS	74.68	M5	2240	0	44
8.573647187	6.114783447	7168	AML 7168	GSM159132	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 33 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159132/suppl/GSM159132.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159132	2	dead	11.56	Rel/PD	8.84	M5	347	1	33
7.626439137	6.141596278	7169	AML 7169	GSM159133	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 54 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159133/suppl/GSM159133.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg		Neg	Neg	cytogenetic intermediate	FAB M2	GSM159133	2	dead	12.39	Rel/PD	9.07	M2	372	1	54
9.227856573	4.906890596	7171	AML 7171	GSM159134	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 22 years	score: FAB unknown	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159134/suppl/GSM159134.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB unknown	GSM159134	2	dead	9.86	Rel/PD	7.13	unknown	296	1	22
7.93191939	4.906890596	7173	AML 7173	GSM159005	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 46 years	score: FAB M2	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159005/suppl/GSM159005.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M2	GSM159005	2	alive	77.17	EFS	77.17	M2	2315	0	46
9.733354341	7.463524373	7174	AML 7174	GSM159006	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 26 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159006/suppl/GSM159006.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	26 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM159006	2	alive	86.05	EFS	86.05	M4	2582	0	26
12.45327063	9.690521858	7177	AML 7177	GSM159007	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: RAEB-t	risk: cytogenetic poor	cebpa: wild type	karyotype: MDS -7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159007/suppl/GSM159007.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	MDS -7(q)	Pos	Neg	cytogenetic poor	RAEB-t	GSM159007	2	dead	8.44	Rel/PD	7.26	RAEB-t	253	1	51
6.659639187	7.516487981	7178	AML 7178	GSM159008	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 28 years	score: FAB M5	risk: unknown	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159008/suppl/GSM159008.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	28 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg		Neg	Neg	unknown	FAB M5	GSM159008	2	dead	19.19	Rel/PD	18.96	M5	576	1	28
7.503030646	5.43629512	7180	AML 7180	GSM159135	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 38 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159135/suppl/GSM159135.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M1	GSM159135	2	alive	94.78	Rel/PD	39.82	M1	2843	0	38
9.373952655	7.427103287	7183	AML 7183	GSM159009	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 51 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159009/suppl/GSM159009.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	pos	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M5	GSM159009	2	dead	30.62	Rel/PD	13.37	M5	919	1	51
8.289096702	5.64385619	7185	AML 7185	GSM159010	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159010/suppl/GSM159010.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M2	GSM159010	2	dead	7.06	NR	2.53	M2	212	1	39
8.421644094	5.325530332	7186	AML 7186	GSM159136	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 40 years	score: FAB M2	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159136/suppl/GSM159136.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	failure	Neg	Pos	unknown	FAB M2	GSM159136	2	dead	26.91	Rel/PD	10.05	M2	807	1	40
10.18003345	7.940754047	7188	AML 7188	GSM159138	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M5	risk: unknown	cebpa: wild type	karyotype: failure	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159138/suppl/GSM159138.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	failure	Neg	Pos	unknown	FAB M5	GSM159138	2	alive	160.6	EFS	160.6	M5	4818	0	51
7.325530332	6.100136671	7190	AML 7190	GSM159139	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 58 years	score: FAB M6	risk: cytogenetic poor	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159139/suppl/GSM159139.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg		Neg	Neg	cytogenetic poor	FAB M6	GSM159139	2	dead	4.73	NR	2.92	M6	142	1	58
9.400025518	7.494255587	7191	AML 7191	GSM159140	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 45 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159140/suppl/GSM159140.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg		Neg	Neg	cytogenetic intermediate	FAB M5	GSM159140	2	dead	9.99	NR	3.38	M5	300	1	45
8.405566974	4.906890596	7272	AML 7272	GSM159141	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: pos	gender: male	age: 48 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159141/suppl/GSM159141.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	48 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	pos	pos	Neg	Other	Neg	Pos	cytogenetic poor	FAB M2	GSM159141	2	alive	224.1	Rel/PD	28.25	M2	6723	0	48
6.694880193	6.364572432	7273	AML 7273	GSM159142	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 22 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159142/suppl/GSM159142.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM159142	2	dead	1.18	NR	0.53	M3	35	1	22
8.101187815	6.687900522	7274	AML 7274	GSM159143	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159143/suppl/GSM159143.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM159143	2	alive	212	EFS	212	M3	6360	0	37
9.140062856	6.809928866	7276	AML 7276	GSM159011	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 59 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159011/suppl/GSM159011.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M4	GSM159011	2	dead	14.69	Rel/PD	6.41	M4	441	1	59
8.169925001	7.116863758	7277	AML 7277	GSM159012	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 31 years	score: FAB M4E	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159012/suppl/GSM159012.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	31 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Pos	Neg	cytogenetic good	FAB M4E	GSM159012	2	alive	190.6	Rel/PD	13.04	M4E	5718	0	31
8.255972742	4.995484519	7301	AML 7301	GSM159013	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 35 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159013/suppl/GSM159013.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	35 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	pos	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159013	2	dead	35.38	D	35.38	M1	1061	1	35
7.39145842	5.112700133	7302	AML 7302	GSM159014	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 50 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: single mutant	karyotype: 	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159014/suppl/GSM159014.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	50 years	pos	single mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg		Neg	Pos	cytogenetic intermediate	FAB M1	GSM159014	2	alive	60.78	EFS	60.78	M1	1823	0	50
7.579693063	5.205548911	7303	AML 7303	GSM159015	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: MDS -Y	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159015/suppl/GSM159015.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	MDS -Y	Neg	Neg	cytogenetic intermediate	RAEB-t	GSM159015	2	dead	12.06	Rel/PD	4.17	RAEB-t	362	1	38
8.162391329	6.699051844	7304	AML 7304	GSM159016	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB M2	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159016/suppl/GSM159016.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M2	GSM159016	2	dead	22.28	Rel/PD	14.72	M2	668	1	60
7.621319301	7.578183968	7305	AML 7305	GSM159017	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 24 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159017/suppl/GSM159017.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	24 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M5	GSM159017	2	dead	40.84	Rel/PD	34.23	M5	1225	1	24
8.623515741	7.584210901	7306	AML 7306	GSM159018	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 51 years	score: FAB M5	risk: cytogenetic poor	cebpa: wild type	karyotype: 11q23	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159018/suppl/GSM159018.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	51 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	11q23	Neg	Neg	cytogenetic poor	FAB M5	GSM159018	2	alive	52.21	EFS	52.21	M5	1566	0	51
8.324630615	5.587964989	7307	AML 7307	GSM159019	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 39 years	score: FAB M1	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159019/suppl/GSM159019.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	39 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M1	GSM159019	2	alive	53.82	EFS	53.82	M1	1615	0	39
7.394891366	5.368069877	7308	AML 7308	GSM159020	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 58 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159020/suppl/GSM159020.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Pos	Neg	cytogenetic intermediate	FAB M0	GSM159020	2	dead	41.17	NR	4.73	M0	1235	1	58
7.938991439	7.623515741	7309	AML 7309	GSM159021	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: female	age: 60 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Pos	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159021/suppl/GSM159021.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	pos	Neg	NN	Pos	Neg	cytogenetic intermediate	RAEB-t	GSM159021	2	dead	15.31	Rel/PD	9.99	RAEB-t	459	1	60
7.964629667	6.334496768	7310	AML 7310	GSM159022	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159022/suppl/GSM159022.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159022	2	dead	2.23	D	2.23	M5	67	1	54
8.791814071	7.675251386	7311	AML 7311	GSM159023	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 53 years	score: RAEB-t	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159023/suppl/GSM159023.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	53 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	RAEB-t	GSM159023	2	dead	9.23	Rel/PD	8.28	RAEB-t	277	1	53
9.073873777	6.930737338	7312	AML 7312	GSM159144	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 33 years	score: RAEB	risk: cytogenetic poor	cebpa: wild type	karyotype: MDS complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159144/suppl/GSM159144.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	33 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	MDS complex	Neg	Neg	cytogenetic poor	RAEB	GSM159144	2	dead	4.07	NR	4.07	RAEB	122	1	33
7.417008587	5.807354922	7313	AML 7313	GSM159024	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 56 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: -5/7(q)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159024/suppl/GSM159024.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	-5/7(q)	Neg	Neg	cytogenetic poor	FAB M0	GSM159024	2	dead	25.95	Rel/PD	9.89	M0	778	1	56
8.15936681	6.722466024	7314	AML 7314	GSM159025	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 41 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159025/suppl/GSM159025.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	41 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M5	GSM159025	2	dead	2.86	Rel/PD	2.86	M5	86	1	41
8.05039286	7.701133155	7315	AML 7315	GSM159026	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 45 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159026/suppl/GSM159026.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	45 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM159026	2	dead	3.06	D	3.06	M4	92	1	45
8.824640581	5.614709844	7316	AML 7316	GSM159027	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 43 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159027/suppl/GSM159027.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	43 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159027	2	dead	8.9	Rel/PD	5.49	M2	267	1	43
8.309248961	7.112700133	7317	AML 7317	GSM159028	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 37 years	score: RAEB-t	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159028/suppl/GSM159028.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	37 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	RAEB-t	GSM159028	2	alive	53.32	EFS	53.32	RAEB-t	1600	0	37
9.336729697	7.553821257	7318	AML 7318	GSM159029	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 60 years	score: FAB unknown	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159029/suppl/GSM159029.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB unknown	GSM159029	2	alive	61.67	EFS	61.67	unknown	1850	0	60
7.438791853	6.475733431	7319	AML 7319	GSM159030	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: female	age: 60 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159030/suppl/GSM159030.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	60 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M4	GSM159030	2	alive	54.57	EFS	54.57	M4	1637	0	60
7.677367292	7.053111336	7320	AML 7320	GSM159171	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 34 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: 	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159171/suppl/GSM159171.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	34 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg		Neg	Pos	cytogenetic intermediate	FAB M5	GSM159171	2	alive	61.8	EFS	61.8	M5	1854	0	34
8.910492832	6.866660751	7402	AML 7402	GSM159031	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 22 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: idt(16)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159031/suppl/GSM159031.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	22 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	idt(16)	Neg	Neg	cytogenetic good	FAB M4	GSM159031	2	alive	194.3	EFS	194.3	M4	5829	0	22
6.795715007	4.906890596	7403	AML 7403	GSM159032	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 46 years	score: FAB M4	risk: cytogenetic good	cebpa: wild type	karyotype: t(8;21)	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159032/suppl/GSM159032.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	t(8;21)	Neg	Neg	cytogenetic good	FAB M4	GSM159032	2	alive	143.7	Rel/PD	58.81	M4	4311	0	46
12.7855342	10.5703301	7405	AML 7405	GSM159033	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 47 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159033/suppl/GSM159033.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	47 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Pos	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic poor	FAB M4	GSM159033	2	dead	8.11	NR	2.5	M4	243	1	47
7.445428759	5.409390936	7406	AML 7406	GSM159034	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 25 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: double mutant	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: pos	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159034/suppl/GSM159034.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	25 years	pos	double mutant	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	female	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159034	2	alive	163.1	Rel/PD	10.64	M1	4893	0	25
8.092228584	7.121015401	7407	AML 7407	GSM159035	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 38 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159035/suppl/GSM159035.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	38 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159035	2	alive	138.3	EFS	138.3	M5	4149	0	38
7.329123596	4.906890596	7408	AML 7408	GSM159145	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: pos	idh2: neg	gender: male	age: 55 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159145/suppl/GSM159145.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	pos	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M1	GSM159145	2	alive	121.6	EFS	121.6	M1	3648	0	55
7.73809226	7.451211112	7409	AML 7409	GSM159146	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M0	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159146/suppl/GSM159146.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M0	GSM159146	2	dead	1.51	NR	1.51	M0	45	1	56
6.99095486	5.82527683	7410	AML 7410	GSM159147	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 57 years	score: FAB M3	risk: cytogenetic good	cebpa: wild type	karyotype: t(15;17)	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159147/suppl/GSM159147.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	57 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	t(15;17)	Neg	Neg	cytogenetic good	FAB M3	GSM159147	2	alive	147.6	Rel/PD	7.39	M3	4428	0	57
10.7198166	5.669593751	7411	AML 7411	GSM159148	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159148/suppl/GSM159148.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159148	2	dead	9.17	Rel/PD	8.44	M2	275	1	54
8.546508661	7.697662633	7413	AML 7413	GSM159150	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 59 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159150/suppl/GSM159150.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	59 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159150	2	dead	69.09	Rel/PD	47.97	M5	2073	1	59
8.434628228	7.133399125	7414	AML 7414	GSM159151	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: female	age: 54 years	score: FAB M5	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159151/suppl/GSM159151.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	54 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	female	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M5	GSM159151	2	dead	23.36	Rel/PD	18.37	M5	701	1	54
8.192785959	6.482202926	7416	AML 7416	GSM159152	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 55 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159152/suppl/GSM159152.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	55 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M4	GSM159152	2	dead	12.02	Rel/PD	9.66	M4	361	1	55
7.442114122	6.94016675	7417	AML 7417	GSM159153	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 29 years	score: FAB M4	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Pos	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159153/suppl/GSM159153.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	29 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Pos	Neg	Neg	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M4	GSM159153	2	dead	7.33	NR	1.94	M4	220	1	29
9.844705764	5.040015679	7418	AML 7418	GSM159154	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 46 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159154/suppl/GSM159154.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159154	2	alive	91.33	EFS	91.33	M1	2740	0	46
7.828453874	6.263034406	7419	AML 7419	GSM159155	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 58 years	score: FAB M4	risk: cytogenetic poor	cebpa: wild type	karyotype: Complex	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159155/suppl/GSM159155.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	58 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Complex	Neg	Neg	cytogenetic poor	FAB M4	GSM159155	2	dead	13.54	NR	1.97	M4	406	1	58
10.44987084	5.368069877	7420	AML 7420	GSM159156	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: pos	gender: male	age: 56 years	score: FAB M1	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159156/suppl/GSM159156.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	pos	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M1	GSM159156	2	dead	21.75	NR	1.51	M1	652	1	56
8.917670434	7.059614856	7421	AML 7421	GSM159157	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 46 years	score: FAB M2	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Pos	flt3 itd mutation: Pos	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159157/suppl/GSM159157.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	46 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Pos	Neg	male	neg	neg	Neg	NN	Neg	Pos	cytogenetic intermediate	FAB M2	GSM159157	2	dead	8.54	Rel/PD	4.21	M2	256	1	46
8.053654418	6.87036472	7423	AML 7423	GSM159158	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 40 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: NN	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Pos	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159158/suppl/GSM159158.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	40 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Pos	male	neg	neg	Neg	NN	Neg	Neg	cytogenetic intermediate	FAB M0	GSM159158	2	dead	2	D	2	M0	60	1	40
7.287250643	5.655351829	7479	AML 7479	GSM159159	Public on Mar 12 2008	Jan 29 2007	Nov 14 2018	RNA	1	Blasts and mononuclear cells, AML patient	Homo sapiens	disease state: Acute myeloid leukemia	cell type: blasts and mononuclear cells	idh1: neg	idh2: neg	gender: male	age: 56 years	score: FAB M0	risk: cytogenetic intermediate	cebpa: wild type	karyotype: Other	npm1: Neg	flt3 itd mutation: Neg	flt3 tkd mutation: Neg	n-ras mutation: Neg	k-ras mutation: Neg	evi1 expression: Neg	cebpa mutation: neg	total RNA	Total RNA was extracted by lysis with guanidium isothiocyanate followed by cesium chloride gradient purification.	biotin	Affymetrix protocol.	9606	Affymetrix protocol.	Affymetrix protocol.	Blasts and mononuclear cells were purified from bone marrow or peripheral blood aspirates of AML patients. Samples contained 80-100 percent blast cells.			MAS5 with global scaling to target value 100, followed by setting all values lower than 30 at 30, and then log2 transformation.	GPL570	Roel,,Verhaak	rverhaak@mdanderson.org	Verhaak	Bioinformatics and Comp Bio	MD Anderson Cancer Center	1400 Pressler St 	Houston	TX	77030	USA	http://odin.mdacc.tmc.edu/~rverhaak/	ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM159nnn/GSM159159/suppl/GSM159159.CEL.gz	54675	Reanalyzed by: GSE119087	Reanalyzed by: GSE122511	56 years	neg	wild type	blasts and mononuclear cells	Acute myeloid leukemia	Neg	Neg	Neg	male	neg	neg	Neg	Other	Neg	Neg	cytogenetic intermediate	FAB M0	GSM159159	2	dead	1.41	NR	1.41	M0	42	1	56
